Recently, VIC-1911, a small molecule oral inhibitor of Aurora A from JSI Indah Pharmaceutical Technology Co.
, received a clinical phase 1 approval issued by the National Medical Products Administration.
The approved indication is the combination with paclitaxel for the treatment of advanced ovarian cancer, Patients with fallopian tube cancer and primary peritoneal cancer
VIC-1911 from JSI Inda is a highly selective Aurora A (Aurora Kinase A) small molecule oral inhibitor, which effectively reduces the myelosuppressive toxicity of pan-Aurora kinase inhibitors developed in the early stage
The drug has completed a phase 1 clinical trial in the United States, and the results show that the compound is well tolerated in humans and has potential anti-cancer activity in multiple tumor types
At present, patients with advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer do not have very effective treatments other than surgery, radiotherapy and chemotherapy
Especially for ovarian cancer, there are about 51,000 new patients and 23,000 deaths in China every year, the 5-year survival rate is 46%, and the recurrence rate of advanced ovarian cancer is as high as 85%
The combination of VIC-1911 and paclitaxel has the potential to prolong patient survival and reduce the recurrence rate
Note: The original text has been deleted